Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

NEW YORK, July 12, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced results from an open-label Phase III study of ERBITUX(R) (Cetuximab) plus a taxane and carboplatin in the first-line treatment for metastatic non-small cell lung cancer (NSCLC). The study did not meet its primary endpoint of progression-free survival (PFS) as assessed by an independent radiology review committee (IRRC). However, key secondary endpoints of the study, including response rate as assessed by the IRRC and PFS as assessed by clinical investigators, were statistically significant and favored the ERBITUX- containing arm.

Known as BMS CA225-099, this study included more than 600 patients from the United States and Canada and was one of several clinical trials intended to establish the role of ERBITUX in the treatment of advanced NSCLC. Data from the largest of these trials, an ongoing multinational Phase III study of ERBITUX plus cisplatin and vinorelbine intended to be the pivotal study for the ERBITUX NSCLC regulatory strategy, are not yet available.

"We consider lung cancer to be a high priority and await the results of other Phase II and Phase III evaluations of ERBITUX in the first- and second- line setting with chemotherapy regimens," stated Eric K. Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems.

"Lung cancer is a devastating disease with few effective treatment options," said Martin Birkhofer, M.D., Vice President, Oncology Global Medical Affairs, Bristol-Myers Squibb. "Efforts to fully interpret these results are ongoing, and the companies plan to submit the data from this study to an upcoming medical meeting in 2007."

About Lung Cancer

The American Cancer Society estimates that in the U.S., more than 213,000 people will be diagnosed with lung cancer in 2007. Lung cancer is the leading cause of cance
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:11/6/2009)...6 DUSA Pharmaceuticals, ...any that is developing and marketing Levulan(®...ocused on patients with common skin conditions, an...ive Officer, will present a corporate overview at ...uesday, November 10, 2009 at 10:00 a.m. ET at the ...
(Date:11/6/2009)...PRNewswire-FirstCall/ -- Roper Industries, Inc. ... definitive agreement to acquire Verathon, Inc., a... The Verathon Board of Directors has approved the ...y regulatory approvals and closing conditions, inc...he closing to be completed in early December. ,...
(Date:11/6/2009)... Facet Solutions, Inc. announced t...hus Orthopedics. The acquisition creates an undisp...ellectual property and clinical experience in post...ents suffering from lumbar spinal stenosis," state...o. "This consolidation further strengthens Facet ...
Breaking Medicine Technology:Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3Facet Solutions Acquires Archus Orthopedics 2YMCA of the USA and Annie E Casey Foundation Honor Five YMCAs for Family Strengthening Excellence 57537 1YMCA of the USA and Annie E Casey Foundation Honor Five YMCAs for Family Strengthening Excellence 57537 2YMCA of the USA and Annie E Casey Foundation Honor Five YMCAs for Family Strengthening Excellence 57537 3YMCA of the USA and Annie E Casey Foundation Honor Five YMCAs for Family Strengthening Excellence 57537 4YMCA of the USA and Annie E Casey Foundation Honor Five YMCAs for Family Strengthening Excellence 57537 5Killing cancer like a vampire slayer 57532 1Killing cancer like a vampire slayer 57532 2Proposal to reintroduce Iberian lynx on abandoned agricultural land 57527 1Proposal to reintroduce Iberian lynx on abandoned agricultural land 57527 2
...Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:AB...ny, discussed results from two pre-clinical studie...ngiogenesis and,rationale for combining nab-paclit...taxel protein-bound particles for injectable,suspe...like,bevacizumab (Avastin(R)) at the 98th American...
...Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:AB...ny, announced results from two pre-clinical studie... acidic and rich in,cysteine) expression in cancer... tumor-targeting technology at the 98th,American A...ng held,April 14-18, 2007 in Los Angeles., "Both p...
Other Medicine Technology:Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 2Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 3Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 4Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 5
(Date:11/8/2009)... New book called "Preventing and Healin...erto Giraldo shows that AIDS is a result of multip...so-called immune system stressor agents, which can...t of all, emotional. , O... – 8, 2009, cell biologists, physicians, che...
(Date:11/8/2009)...ov. 7 Today, the House ...r, Dahlkemper, Smith, Ellsworth and Lipinski amend...t" (H.R. 3962). The amendment maintains the curren...n and for benefits packages that include abortion....eive affordability credits and those who do not, c...
(Date:11/8/2009)...ift Passage of H.R. 3961 to Secure the Stability o...wswire/ -- Statement Attributable to: J. James Roh.... ,, (Logo: http://www.newscom.com/cgi-bin/pr...assage of the House health reform bill, which will...hysicians and calls for swift passage of H.R. 3961...
(Date:11/8/2009)...lif., Nov. 8 March of D...s luncheon to recognize prominent individuals who ...o are role models for March of Dimes commitment to...ch of Dimes November Prematurity Awareness Month c... to join the fight for preemies! ,, (Photo: h...
(Date:11/7/2009)... Coleman (CT), David A. Cook (GA), Louis J. Goodma... Honored ,, CHICAGO, Nov. 7 /PRNewswire-USNews...day presented five medical society executive leade...tions to the goals and ideals of the medical profe...-annual policy making meeting in Houston. ,, (...
Breaking Medicine News(10 mins):Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3Health News:AMA Honors Medical Society Executives 2
...ecent research has revealed that age-related macul...y smokers as nonsmokers. However it was also found...east twice weekly are almost half as likely to hav...Eye and Ear Infirmary, which is affiliated with Ha...
... new study suggests that male circumcision could s... The findings that has been published in the J...ished in 2005, that suggested circumcision reduced...Africa to predict the potential impact. The ...
... study detailing the rampant sexual abuse in NHS m... the Health Department in UK eight months ago. //T...d sexual harassment have occurred in the last 24 m... the report is not yet complete and will be publis...
... new study in the July issue of Archives of Genera... and are in fact more prone to depression. //The s...rsons were at a 25 percent increased risk of devel...th issue because both of these conditions are so c...
...he Malabar Institute of Medical Sciences (MIMS) is... in Kerala. // MIMS, run by a group of non-r...eration Council (GCC) countries, has already acqui...MS chairman Azad Moopen told the newspaper that th...
...hina today agreed to reconduct lab tests to find o...se in Beijing as early as 2003, after eight of its... The Chinese Ministry of Health said it was co...r human avian influenza, parallel laboratory tests...
Other Medicine News:Health News:Save your Vision with Fish Oil and Quitting Smoking 2Health News:Practise Of Male Circumcision In Africa May Reduce HIV Risks 2
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
Medicine Products: